
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded slow release capsule containing pentoxifylline hydrochloride, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing pentoxifylline are listed in tablet form. No finished pentoxifylline product of any kind is listed in capsule form.
This is a solid, nonaqueous dose form. Under USP <795>, nonaqueous preparations carry longer default beyond-use dates than water-containing ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Pentoxifylline is a xanthine-derived agent that improves blood flow; compounding pharmacies prepare it by prescription, including in topical creams.
Pentoxifylline is a xanthine derivative, related to caffeine and theophylline, classed as a hemorheologic agent because it lowers blood viscosity. It makes red blood cells more flexible, reduces platelet clumping and inhibits phosphodiesterase, effects that help blood move through small vessels. Trental (pentoxifylline extended-release tablets) and generic versions are FDA-approved for intermittent claudication caused by chronic occlusive arterial disease of the limbs; the label notes it can improve function and symptoms but is not meant to replace surgical treatment. A 2020 National Academies report noted that pentoxifylline is used in some compounded topical pain creams. A prescriber might order pentoxifylline compounded in a form, strength or combination that is not manufactured, including topical preparations. Compounded preparations are not FDA-approved and require a prescription.
Pentoxifylline has no boxed warning. Do not use it after recent bleeding in the brain or retina, or if you cannot tolerate pentoxifylline or related xanthines such as caffeine, theophylline or theobromine. Bleeding has been reported, with or without NSAIDs, anticoagulants or antiplatelet drugs, and people taking warfarin need more frequent clotting tests. It can raise theophylline levels; strong CYP1A2 inhibitors such as ciprofloxacin or fluvoxamine, and cimetidine, can raise pentoxifylline levels; and it can slightly lower blood pressure. Chest pain, low blood pressure, irregular heartbeat, upset stomach, nausea, dizziness and headache can occur. Kidney or liver impairment increases exposure. The label advises use in pregnancy only if the benefit justifies the risk. LactMed reports pentoxifylline passes poorly into milk and is not expected to harm a breastfed infant, especially one older than 2 months. Talk to your prescriber or pharmacist about side effects.
Pentoxifylline lowers blood viscosity and improves erythrocyte deformability; StatPearls adds phosphodiesterase inhibition with increased cAMP, reduced thromboxane and platelet aggregation, increased fibrinolysis and TNF-alpha inhibition. Per the Trental label, oral absorption is nearly complete with first-pass metabolism; after an oral solution, parent and metabolites peak within 1 hour. Parent half-life is 0.4 to 0.8 hours and metabolite half-lives 1 to 1.6 hours, with nonlinear kinetics; excretion is almost entirely urinary, mainly as Metabolite V. Older adults and patients with hepatic or renal impairment have higher exposure. Labeled indication: Trental for intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. StatPearls lists off-label use for venous ulcers, severe alcoholic hepatitis when corticosteroids are contraindicated, and osteoradionecrosis. Prescribers have ordered compounded pentoxifylline in topical pain creams; the National Academies review found limited data for topical pentoxifylline alone and noted a concern about blood pressure lowering. Monitor PT/INR with vitamin K antagonists, theophylline levels, blood pressure, and hematocrit or hemoglobin in patients at bleeding risk. Dosing is per prescriber. Pentoxifylline is not a controlled substance.
Swallow the capsule whole with fluid. Do not crush, chew, divide or open it, and do not dissolve it in liquid, because that can release the full dose at once. Take it at the same times each day as your label directs. Slow release forms are not meant for feeding tubes; ask your pharmacist if you need a different form.
These are nonaqueous capsules, so a USP <795> default beyond-use date of up to 180 days usually applies. Store in a closed container at room temperature, away from heat, moisture and direct light, and out of reach of children. Discard after the beyond-use date on the label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth